Trial document





This trial has been registered retrospectively.
drksid header

  DRKS00000242

Trial Description

start of 1:1-Block title

Title

CONKO-006:Additive therapy in R1-resected pancreatic cancer with gemcitabine
plus sorafenib vs. Gemcitabine plus placebo over 12 months - a double blind, placebo-controlled Phase IIb trial

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

CONKO-006

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

http://www.tumorcenter.de

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Patients with pancreatic cancer have a hig risk of relaps of the disease even after a well performed operation. This is especially true for those patients were it was not possible to keep a safety margin to the healthy tissue (so called R1-resection). A chemotherapy with Gemcitabine is actually the standard of care after an operation of pancreatic cancer. In our study CONKO-006 we will try to improve the prognosis of the patients with R-1 resecion by intensifying this adjuvant therapy. The duration of treatment will be 12 months (instead of 6 months) and to the chemotherapy of Gemcitabine a new oral medicament will be added that may influence the vascular feeding of tumour cells.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

CONKO-006 is a randomized, double-blind placebo-controlled multi-center phase IIb study in patients with R1-resection of pancreatic cancer with two treatment groups. The aim of the study is to demonstrate the usefulness of the additional treatment with the multikinase-inhibitor Sorafebine in combination with the standard therapy of gemcitabine and the efficacity of a prolongation of adjuvant therapy from 6 to 12 months. The antitumoral effect of Sorafenibe is due to the inhibition of tumor proliferation (by inhibiton of raf-kinases and the Raf/MEK-ERK-pathway) and of the tumor specific angiogenesis (by inhibition of VEGF, EGF and PDGF-receptors). Primary endpoint of the study is to compare disease free survival rate 18 months after start of treatment in both treatment groups following potentially curative surgery. A prolongation of disease free survival after 18 months from 42% to 60%, assuming an exponential survival curve, means a prolongation of the median progression free survival from 14,4 to 24,4 months. This calculations are based on the datas of the CONKO-001-study. In this trial the disease free survival for the subgroup of patients after R1-resection was improved from 5,5 months to 15,8 months by a 6 months adjuvant therapy with gemcitabine1. For a few of patients with pancreatic cancer, definitive curation seems possible by adjuvant therapy.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00000242
  •   2010/03/04
  •   [---]*
  •   yes
  •   Approved
  •   ZS EK 11 487/07, Ethik-Kommission des Landes Berlin
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   U1111-1114-0963 
  •   2007-000718-35 
  •   4033485 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C25 -  Malignant neoplasm of pancreas
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Arm A:
    Sorafenib 400 mg twice daily p.o. plus Gecitabine 1000 mg/ m² day 1, 8, 15 repetition day 29
    Duration: 12 Month
  •   Arm B:
    Placebo twice daily plus Gemcitabine 1000 mg/m² day 1, 8, 15 repetition day 29
    Duration: 12 Month
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, investigator/therapist
  •   Placebo
  •   Treatment
  •   Parallel
  •   IIb
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Relaps-free survival

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Overall survival
Safety and tolerability
Evaluation of prognostic factors

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2008/02/08
  •   127
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Histological confirmed diagnosis of an adenocarcinoma of the pancreas, Standardised surgery for tumor resection, e. g. partial pancreatoduodenectomy
(Kausch-Whipple), pylorus-sparing partial pancreatoduodenectomy
(PPPD), pancreas leftresection or total pancreatectomy,
Result of resection: R1, No previous neoadjuvant therapy (chemotherapy or radiation), Performance-Status according to Karnofsky-Scale > 60 %, Patient compliance and geographical situation allowing an adequate
follow up, especially the willingness to visit the same center regulary
for at least 2 years after surgery, Sufficient bone marrow capacity: WBC > 3.5 /nl, platelets
> 100 /nl, haemoglobin > 8 g/dl, Written informed consent of the patient prioral any precedure in
connection with the study, Male and female patients with an age of at least 18 years, Initiation of the adjuvant therapy as soon as possible postoperative.
Soonest 4 weeks after resection but not before completion of
the wound healing, but at latest in between 8 weeks after resection.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Seriouses systemic disease (with life expectance < 6 months) according to estimation of the investigator, active infection > Grad 2 NCI-CTCAE v3.0, Known HIV infection, Serious systemic disease: Uncontrolled hypertension, ingestive heart failure NYHA III - IV, symptomatic coronary heart disease, uncontrolled cardial arrhythmia > grade II, peripher arterial disease > stage IIb, International Normalized Ratio (INR) > 1.5, prolongation of the activated partial prothrombin time (aPTT) > 1.5 x UNL (upper normal limit), transaminases > 3x UNL, Postoperative measurable tumorlesion, Pregnant or breast-feeding women. Women of child-bearing potential must have an negative pregnancy test performed 7 days prior to start of the treatment, Sexually active males or females with child-bearing potential unwilling to practice sufficient contraception during the study and for 3 months after end of the study medication., Known allergical reactions against the study drugs or the substances included therein, Patients undergoing dialysis, Interstitial pneumonia or symptomatic fibrosis of the lung, Need of immunosuppressive therapy (e. g. transplantation), Severe non-healing wounds, ulcers or bone fracturs, Participation in another experimental clinical trial within 4 weeks prior to entry into the study, Previous or ongoing narcotic drug, medication- or alcohol abuse, Patients which are not able to take in oral drugs, need parenteral nutrition,are known to have an insufficient gastrointestinal resorption or suffer from acute stomac ulcer, Other primary malignancy in the patient's history (except for successfully treated basalioma or carcinoma in situ of the cervix uteri), patients ordered to be hospitalized by legal decision

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Charité-Universitätsmedizin Berlin
    • Augustenburger Platz 1
    • 13353  Berlin
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Charité - Universitätsmedizin Berlin CharitéCentrum für Tumormedizin Medizinische Klinik mit Schwerpunkt Hämatologie/ Onkologie
    • Ms.  Dr. med.  Marianne  Sinn 
    • Augustenburger Platz 1
    • 13353  Berlin
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Charité - Universitätsmedizin Berlin CharitéCentrum für Tumormedizin Medizinische Klinik mit Schwerpunkt Hämatologie/ Onkologie
    • Ms.  Dr.  Marianne  Sinn 
    • Augustenburger Platz 1
    • 13353  Berlin
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bayer Vital GmbH
    • Kaiser-Wilhelm-Allee
    • 51368  Leverkusen
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up continuing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.